Comparison between lergotrile and bromocriptine in parkinsonism.

P. F. Teychenne, Ronald Pfeiffer, S. M. Bern, D. McInturff, D. B. Calne

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The therapeutic and adverse effects of two ergot derivatives, bromocriptine and lergotrile, were compared in idiopathic parkinsonism. At both low (50 mg daily) and high (150 mg daily) dosage there was a similar but not identical profile of response. Initially, lergotrile tended to induce more severe but always transient hypotension. At higher doses, bromocriptine caused more dyskinesia. Neurological deficits improved with increasing doses up to an average daily level of 80 to 150 mg of ergot derivatives combined with levodopa, 450 to 1,150 mg, and carbidopa, 45 to 115 mg. However, efficacy often declined at the highest doses of antiparkinsonian agents. Adverse effects caused by ergot derivatives are more common with dosages greater than 100 mg per day. In general, the best overall therapeutic results with bromocriptine and lergotrile were obtained in the dose range of 50 to 100 mg daily for each. It is concluded that bromocriptine and lergotrile are similar in their therapeutic properties and that both are comparable in efficacy to levodopa plus carbidopa (though optimal results are commonly obtained by combining submaximal doses of levodopa with ergot derivatives). The role for each drug in the treatment of parkinsonism is likely to be determined by factors such as cost (bromocriptine) and hepatotoxicity (lergotrile).

Original languageEnglish (US)
Pages (from-to)319-324
Number of pages6
JournalAnnals of Neurology
Volume3
Issue number4
StatePublished - Apr 1978
Externally publishedYes

Fingerprint

Bromocriptine
Parkinsonian Disorders
Levodopa
Carbidopa
Antiparkinson Agents
Dyskinesias
Therapeutic Uses
Hypotension
lergotrile
Costs and Cost Analysis
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Teychenne, P. F., Pfeiffer, R., Bern, S. M., McInturff, D., & Calne, D. B. (1978). Comparison between lergotrile and bromocriptine in parkinsonism. Annals of Neurology, 3(4), 319-324.

Comparison between lergotrile and bromocriptine in parkinsonism. / Teychenne, P. F.; Pfeiffer, Ronald; Bern, S. M.; McInturff, D.; Calne, D. B.

In: Annals of Neurology, Vol. 3, No. 4, 04.1978, p. 319-324.

Research output: Contribution to journalArticle

Teychenne, PF, Pfeiffer, R, Bern, SM, McInturff, D & Calne, DB 1978, 'Comparison between lergotrile and bromocriptine in parkinsonism.', Annals of Neurology, vol. 3, no. 4, pp. 319-324.
Teychenne PF, Pfeiffer R, Bern SM, McInturff D, Calne DB. Comparison between lergotrile and bromocriptine in parkinsonism. Annals of Neurology. 1978 Apr;3(4):319-324.
Teychenne, P. F. ; Pfeiffer, Ronald ; Bern, S. M. ; McInturff, D. ; Calne, D. B. / Comparison between lergotrile and bromocriptine in parkinsonism. In: Annals of Neurology. 1978 ; Vol. 3, No. 4. pp. 319-324.
@article{9bcdd757f4bf48df83edd2cdec745252,
title = "Comparison between lergotrile and bromocriptine in parkinsonism.",
abstract = "The therapeutic and adverse effects of two ergot derivatives, bromocriptine and lergotrile, were compared in idiopathic parkinsonism. At both low (50 mg daily) and high (150 mg daily) dosage there was a similar but not identical profile of response. Initially, lergotrile tended to induce more severe but always transient hypotension. At higher doses, bromocriptine caused more dyskinesia. Neurological deficits improved with increasing doses up to an average daily level of 80 to 150 mg of ergot derivatives combined with levodopa, 450 to 1,150 mg, and carbidopa, 45 to 115 mg. However, efficacy often declined at the highest doses of antiparkinsonian agents. Adverse effects caused by ergot derivatives are more common with dosages greater than 100 mg per day. In general, the best overall therapeutic results with bromocriptine and lergotrile were obtained in the dose range of 50 to 100 mg daily for each. It is concluded that bromocriptine and lergotrile are similar in their therapeutic properties and that both are comparable in efficacy to levodopa plus carbidopa (though optimal results are commonly obtained by combining submaximal doses of levodopa with ergot derivatives). The role for each drug in the treatment of parkinsonism is likely to be determined by factors such as cost (bromocriptine) and hepatotoxicity (lergotrile).",
author = "Teychenne, {P. F.} and Ronald Pfeiffer and Bern, {S. M.} and D. McInturff and Calne, {D. B.}",
year = "1978",
month = "4",
language = "English (US)",
volume = "3",
pages = "319--324",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Comparison between lergotrile and bromocriptine in parkinsonism.

AU - Teychenne, P. F.

AU - Pfeiffer, Ronald

AU - Bern, S. M.

AU - McInturff, D.

AU - Calne, D. B.

PY - 1978/4

Y1 - 1978/4

N2 - The therapeutic and adverse effects of two ergot derivatives, bromocriptine and lergotrile, were compared in idiopathic parkinsonism. At both low (50 mg daily) and high (150 mg daily) dosage there was a similar but not identical profile of response. Initially, lergotrile tended to induce more severe but always transient hypotension. At higher doses, bromocriptine caused more dyskinesia. Neurological deficits improved with increasing doses up to an average daily level of 80 to 150 mg of ergot derivatives combined with levodopa, 450 to 1,150 mg, and carbidopa, 45 to 115 mg. However, efficacy often declined at the highest doses of antiparkinsonian agents. Adverse effects caused by ergot derivatives are more common with dosages greater than 100 mg per day. In general, the best overall therapeutic results with bromocriptine and lergotrile were obtained in the dose range of 50 to 100 mg daily for each. It is concluded that bromocriptine and lergotrile are similar in their therapeutic properties and that both are comparable in efficacy to levodopa plus carbidopa (though optimal results are commonly obtained by combining submaximal doses of levodopa with ergot derivatives). The role for each drug in the treatment of parkinsonism is likely to be determined by factors such as cost (bromocriptine) and hepatotoxicity (lergotrile).

AB - The therapeutic and adverse effects of two ergot derivatives, bromocriptine and lergotrile, were compared in idiopathic parkinsonism. At both low (50 mg daily) and high (150 mg daily) dosage there was a similar but not identical profile of response. Initially, lergotrile tended to induce more severe but always transient hypotension. At higher doses, bromocriptine caused more dyskinesia. Neurological deficits improved with increasing doses up to an average daily level of 80 to 150 mg of ergot derivatives combined with levodopa, 450 to 1,150 mg, and carbidopa, 45 to 115 mg. However, efficacy often declined at the highest doses of antiparkinsonian agents. Adverse effects caused by ergot derivatives are more common with dosages greater than 100 mg per day. In general, the best overall therapeutic results with bromocriptine and lergotrile were obtained in the dose range of 50 to 100 mg daily for each. It is concluded that bromocriptine and lergotrile are similar in their therapeutic properties and that both are comparable in efficacy to levodopa plus carbidopa (though optimal results are commonly obtained by combining submaximal doses of levodopa with ergot derivatives). The role for each drug in the treatment of parkinsonism is likely to be determined by factors such as cost (bromocriptine) and hepatotoxicity (lergotrile).

UR - http://www.scopus.com/inward/record.url?scp=0017953547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017953547&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 319

EP - 324

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 4

ER -